The goal of this activity is for learners to be better able to recognize the requirements for biosimilarity and interchangeability of biologic agents, the role of biosimilars in IBD management, and the potential clinical and economic impact of biosimilars.
More Information
Faculty:
Raymond K. Cross, MD, MS, AGAF, FACG
Professor of Medicine
Division of Gastroenterology and Hepatology
Director, Inflammatory Bowel Disease Program
Co-Director, Digestive Health Center
University of Maryland School of Medicine
Baltimore, Maryland
Roderick Smith, MS
Senior Medical Education Director
Medscape, LLC
Esther Nyarko, PharmD
Director, Accreditation and Compliance
Medscape, LLC
Learning Objectives:
Upon completion of this activity, participants will:
- Compare regulatory criteria for interchangeability with criteria for approval of biosimilar agents
- Summarize clinical data for biosimilar anti-tumor necrosis factor (TNF) agents in the treatment of IBD
- Explain biosimilar agents to patients to facilitate shared decision-making
Disclosures
Raymond K. Cross, MD, MS, AGAF, FACG, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; Adiso; Bristol-Myers Squibb Company; Fresenius; Fzata; Kabi; Magellan Health; Pfizer, Inc.; Samsung Bioepis; Sebela Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.
Research funding from: Janssen Biotech
Monetary compensation for an executive role from: CorEvitas; IBD Education Group
Roderick Smith, MS has no relevant financial relationships to disclose
Esther Nyarko, PharmD has no relevant financial relationships to disclose
Accreditation Statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationships with ineligible companies held within the past 24 months. The AGA Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.
CME expiration date: Sept. 29, 2024
